Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD), a biopharmaceutical company developing small molecule drugs for treating central nervous system disorders, faced a setback at the Psychopharmacologic Drugs Advisory Committee (PDAC) meeting for pimavanserin, a drug intended to treat hallucinations and delusions associated with Alzheimer’s disease psychosis. The...
Biotech Companies continue to show resurgence even in these challenging times, with more and more companies persevering with bringing their clinical candidates to fruition. While Vaccine development and therapeutics to combat the COVID-19 pandemic are at the forefront of development activities in the biotech sector,...
The Global Market for Insomnia is estimated to reach $5,488 million by 2023 from $4,093 million in 2016 at a CAGR of 4.2% according to a report titled “Insomnia Market by Therapy Type [Non-pharmacological Therapy (Hypnotherapy, Cognitive Behavioral Therapy, Medical Devices, and Other Non-pharmacological Therapy) and Pharmacological Therapy (Prescription...
